Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERALD: elacestrant versus standard endocrine monotherapy after CDK4/6 inhibitor in ER-positive, HER2-negative advanced breast cancer
MOH_2019-07-21_007273Phase 3Recruiting
- Sponsor
- Radius Health Inc
- Start
- Apr 2019
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Elacestrant with Standard of care endocrine therapy (2 arms). Started Apr 2019; status: recruiting.
02
Drugs
elacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2019-07-21_007273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-07-21_007273.